Richard Scheller Net Worth

The estimated Net Worth of Richard H Scheller is at least $13.6 Milhão dollars as of 22 August 2024. Richard Scheller owns over 44,250 units of BridgeBio Pharma Inc stock worth over $979,650 and over the last 10 years he sold BBIO stock worth over $11,402,310. In addition, he makes $1,199,990 as Chairman of Research and Development e Director at BridgeBio Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Richard Scheller BBIO stock SEC Form 4 insiders trading

Richard has made over 18 trades of the BridgeBio Pharma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 44,250 units of BBIO stock worth $228,330 on 22 August 2024.

The largest trade he's ever made was selling 66,241 units of BridgeBio Pharma Inc stock on 2 July 2021 worth over $1,867,996. On average, Richard trades about 7,795 units every 64 days since 2015. As of 22 August 2024 he still owns at least 35,000 units of BridgeBio Pharma Inc stock.

You can see the complete history of Richard Scheller stock trades at the bottom of the page.

Richard Scheller biography

Dr. Richard Henry Scheller Ph.D. serves as Chairman of Research and Development, Director of the Company. Dr. Scheller served as the Chief Science Officer and Head of Therapeutics at 23andMe, a personal genetics company, from 2015 to 2019. Previously, Dr. Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc., a biotechnology corporation, from February 2001 to December 2014. From January 2009 to December 2014, Dr. Scheller was also a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd, a pharmaceutical company. Dr. Scheller currently serves as a member of the board of directors of Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, ORIC Pharmaceuticals, Inc., a biopharmaceutical company, Affinita Biotech, Inc., a preclinical stage biotech company and Alector, Inc. (Nasdaq: ALEC), a clinical-stage biopharmaceutical company. Dr. Scheller holds a B.Sc. in Biochemistry from the University of Wisconsin-Madison and a Ph.D. in Chemistry from the California Institute of Technology. He completed his post-doctorate in Molecular Neurobiology at Columbia University and was also a post-doctorate fellow at California Institute of Technology. Dr. Scheller’s qualifications to serve on our Board of Directors include his scientific background and his senior management experience in the pharmaceutical industry.

What is the salary of Richard Scheller?

As the Chairman of Research and Development e Director of BridgeBio Pharma Inc, the total compensation of Richard Scheller at BridgeBio Pharma Inc is $1,199,990. There are 9 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.

How old is Richard Scheller?

Richard Scheller is 67, he's been the Chairman of Research and Development e Director of BridgeBio Pharma Inc since 2019. There are 4 older and 18 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.

What's Richard Scheller's mailing address?

Richard's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at BridgeBio Pharma Inc

Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo, eGenetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.

What does BridgeBio Pharma Inc do?

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.

Complete history of Richard Scheller stock trades at Xenon Pharmaceuticals Inc, BridgeBio Pharma Inc, Oric Pharmaceuticals, eAlector

BridgeBio Pharma Inc executives and stock owners

BridgeBio Pharma Inc executives and other stock owners filed with the SEC include:

• Neil Kumar,
  Chief Executive Officer, Director
• Charles Homcy,
  Chairman of Pharmaceuticals, Lead Director
• Uma Sinha,
  Chief Scientific Officer
• Brian Stephenson,
  Chief Financial Officer
• Eric Aguiar,
  Independent Director
• Ali Satvat,
  Independent Director
• Jennifer Cook,
  Independent Director
• Dr. Neil Kumar Ph.D.,
  Co-Founder, CEO & Director
• Dr. Brian C. Stephenson C.F.A., Ph.D.,
  CFO, Sec. & Principal Accounting Officer
• James Momtazee,
  Independent Director
• Richard Scheller,
  Chairman of Research and Development, Director
• Dr. Michael Thomas Henderson M.D.,
  Chief Bus. Officer
• Dr. Charles J. Homcy M.D.,
  Chairman of Pharmaceuticals & Lead Director
• Dr. Richard H. Scheller Ph.D.,
  Chairman of R&D and Director
• Dr. Cameron Turtle DPHIL, Ph.D.,
  Chief Strategy Officer
• Randal Scott,
  Independent Director
• Brenton Saunders,
  Independent Director
• Andrew Lo,
  Independent Director
• Ronald Daniels,
  Independent Director
• Michael Henderson,
  Chief Business Officer
• Cameron Turtle,
  Senior Vice President - Portfolio Management and Corporate Development
• Frank Mccormick,
  Chairman of Oncology
• Dr. Frank McCormick Ph.D.,
  Chairman of Oncology
• Grace Rauh,
  VP of Communications
• Dr. Uma Sinha Ph.D.,
  Chief Scientific Officer
• Yi Ching Yau,
  Chief Accounting Officer
• Genetic Disorder L.P.Kkr Ge...,
  
• Management Holdings L.P.Kkr...,
  
• Douglas A. Dachille,
  
• Fred Hassan,
  
• Global Performance Llc Viki...,
  
• Global Investors Lp Viking ...,
  
• Genetic Disorder L.P.Robert...,
  
• Yi Ching Yau,
  Chief Accounting Officer
• Brian M. Stolz,
  Chief Operating Officer
• Hannah Valantine,
  
• Brent L Saunders,
  Director
• Andrea Ellis,
  
• Global Investors Lp Viking ...,
  
• Thomas Trimarchi,
  President and COO